CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CDX-1140’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CDX-1140 overview

CDX-1140 is under development for the treatment of lymphoma like advanced diffuse large B-cell lymphoma (DLBCL), metastatic pancreatic adenocarcinoma pancreatic ductal adenocarcinoma, mantle cell lymphoma, or indolent B-cell lymphoma, metastatic or unresectable triple negative breast cancer, metastatic melanoma, solid tumor, bladder cancer, urothelial cancer, follicular lymphoma, non-small cell lung cancer, breast cancer, colorectal cancer, gastric cancer, esophageal cancer, renal cell cancer, hepatic cancer, ovarian cancer, fallopian and peritoneal, head and neck cancer, bile duct cancer, endometrial cancer and pancreatic adenocarcinoma. The drug candidates target B-cell surface antigen CD40. It is administered through intravenous route.

Celldex Therapeutics overview

Celldex Therapeutics (Celldex) is a bio-pharmaceutical company that discovers, develops, and commercializes targeted immunotherapy and other biologics for the treatment of various types of cancers. The company’s developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), protein-based therapeutics, immune system modulators and vaccine for unmet medical needs. Its key products in development include CDX-1140; CDX-527, CDX-0159. Celldex’s products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell carcinoma. It operates a manufacturing facility in Massachusetts, the US, and research laboratories in Massachusetts, New Jersey, and Connecticut. Celldex is headquartered in Hampton, New Jersey, the US.

For a complete picture of CDX-1140’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.